Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability

European Journal of Pharmacology

Volumn 587, Issue 1-3, 2008, Pages 309-316

  Nieminen, Riina ^a   Vuolteenaho, Katriina ^a   Riutta, Asko ^a   Kankaanranta, Hannu ^a   van der Kraan, Peter M ^b   Moilanen, Teemu ^a,c   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Coxa Hospital for Joint Replacement ^*  (Finland)

Author keywords

Aurothiomalate; Chondrocyte; Cyclooxygenase 2

Indexed keywords

AUROTHIOMALATE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DACTINOMYCIN; HUR PROTEIN; HYDROXYCHLOROQUINE; INTERLEUKIN 1BETA; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; PROSTAGLANDIN E2; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CARTILAGE; CARTILAGE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HALF LIFE TIME; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA DEGRADATION; RNA STABILITY; SYNOVIAL FLUID;

ANTIRHEUMATIC AGENTS; BLOTTING, WESTERN; CARTILAGE; CHONDROCYTES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GOLD SODIUM THIOMALATE; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLIUM SALTS;

EID: 44349155885     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.016     Document Type: Article

References (62)

1. Abramson S.B., and Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv. Drug Deliv. Rev. 58 (2006) 212-225
2. Amin A.R., Attur M., Patel R.N., Thakker G.D., Marshall P.J., Rediske J., Stuchin S.A., Patel I.R., and Abramson S.B. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J. Clin. Invest. 99 (1997) 1231-1237
3. Amin A.R., Attur M., and Abramson S.B. Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr. Opin. Rheum. 11 (1999) 202-209
4. 2 stimulation. Exp. Cell Res. 222 (1996) 379-384
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
6. Denkert C., Weichert W., Winzer K.J., Muller B.M., Noske A., Niesporek S., Kristiansen G., Guski H., Dietel M., and Hauptmann S. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin. Cancer Res. 10 (2004) 5580-5586
7. Denkert C., Koch I., von Keyserlingk N., Noske A., Niesporek S., Dietel M., and Weichert W. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod. Pathol. 19 (2006) 1261-1269
8. Dixon D.A., Kaplan C.D., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J. Biol. Chem. 275 (2000) 11750-11757
9. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108 (2001) 1657-1665
10. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., and Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
11. Fernandez P., Guillen M.I., Gomar F., Aller E., Molina P., and Alcaraz M.J. A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis. Biochem. Pharmacol. 68 (2004) 417-421
12. Forestier J. Rheumatoid arthritis and its treatment by gold salts. J. Lab. Clin. Med. 20 (1935) 827-840
13. Freyberg R.H., Block W.D., and Levey S. Metabolism, toxicity and manner of action of gold compounds used in the treatment of arthritis. I. Human plasma and synovial fluid concentration and urinary excretion of gold during and following treatment with gold sodium thiomalate, gold sodium thiosulfate, and colloidal gold sulfide. J. Clin. Invest. 20 (1941) 401-412
14. Geng Y., Blanco F.J., Cornelisson M., and Lotz M. Regulation of cyclooxygenase expression in normal human articular chondrocytes. J. Immunol. 155 (1995) 796-801
15. Gerber R.C., Paulus H.E., Bluestone R., and Pearson C.M. Clinical response and serum gold levels in chrysotherapy. Lack of correlation. Ann. Rheum. Dis. 31 (1972) 308-310
16. Goldring M.B., and Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators. Clin. Orthop. Rel. Res. 427S (2004) S37-S46
17. Good P.J. The role of elav-like genes, a conserved family encoding RNA-binding proteins, in growth and development. Semin. Cell Dev. Biol. 8 (1997) 577-584
18. Harding P., Balasubramanian L., Swegan J., Stevens A., and Glass W.F. Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells. Kidney Int. 69 (2006) 1578-1585
19. 2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 46 (2002) 1789-1803
20. Healy Z.R., Lee N.H., Gao X., Goldring M.B., Talalay P., Kensler T.W., and Konstantopoulos K. Divergent responses of chondrocytes and endothelial cells to shear stress: cross-talk among COX-2, the phase 2 response, and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 14010-14015
21. Herschman H.R. Regulation and function of prostaglandin synthase 2/cyclooxygenase II. In: Curtis-Prior P. (Ed). The Eicosanoids (2004), John Wiley and Sons, Ltd, England 43-52
22. Jin S.H., Kim T.I., Yang K.M., and Kim W.H. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur. J. Pharm. 558 (2007) 14-20
23. Katsanou V., Papadaki O., Milatos S., Blackshear P.J., Anderson P., Kollias G., and Kontoyiannis D.L. HuR as a negative posttranscriptional modulator in inflammation. Mol. Cell 19 (2005) 777-789
24. Lacki J.K., Klama K., Mackiewicz S.H., Mackiewicz U., and Muller W. Circulating interleukin-10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. Inflamm. Res. 44 (1995) 24-26
25. Lasa M., Brook M., Saklatvala J., and Clark A.R. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol. Cell. Biol. 21 (2001) 771-780
26. Lehman A.J., Esdaile J.M., Klinkhoff A.V., Grant E., Fitzgerald A., Canvin J., and The METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. Arthritis Rheum. 52 (2005) 1360-1370
27. Loetscher P., Dewald B., Baggiolini M., and Seitz M. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine 6 (1994) 162-170
28. Luukkainen R., Isomäki H., and Kajander A. Effect of gold treatment on the progression of erosions in RA patients. Scand. J. Rheumatol. 6 (1977) 123-127
29. Mastbergen S.C., Jansen N.W.D., Bijlsma J.W.J., and Lafeber F.P.J.G. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res. Ther. 8 (2006) R2
30. Moilanen E., Alanko J., Seppälä E., and Vapaatalo H. Effects of antirheumatic drugs on leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Agents Actions 24 (1988) 387-394
31. Mrena J., Wiksten J.P., Thiel A., Kokkola A., Pohjola L., Lundin J., Nordling S., Ristimäki A., and Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin. Cancer Res. 11 (2005) 7362-7368
32. Munro R., Hampson R., McEntegart A., Thomson E.A., Madhok R., and Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann. Rheum. Dis. 57 (1998) 88-93
33. Nabors L.B., Furneaux H.M., and King P.H. HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissues. J. Neuroimmunol. 92 (1998) 152-159
34. Needleman P., Turk J., Jakschik B.A., Morrison A.R., and Lefkowith J.B. Arachidonic acid metabolism. Ann. Rev. Biochem. 55 (1986) 69-102
35. Nieminen R., Leinonen S., Lahti A., Vuolteenaho K., Jalonen U., Kankaanranta H., Goldring M.B., and Moilanen E. Inhibitors of mitogen-activated protein kinases downregulate COX-2 expression in human chondrocytes. Mediators Inflamm. 2005 (2005) 249-255
36. Nieminen R., Lahti A., Jalonen U., Kankaanranta H., and Moilanen E. JNK inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages. Int. Immunopharmacol. 6 (2006) 987-996
37. Noriega J.L.R., and Harth M. Pharmacology of gold compounds in rheumatoid arthritis. Can. J. Clin. Pharmacol. 4 (1997) 127-136
38. Ohta A., Louie J.S., and Uitto J. Collagenase production by human mononuclear cells in culture: inhibition by gold containing compounds and other antirheumatic agents. Ann. Rheum. Dis. 45 (1986) 996-1003
39. 2 production by polymorphonuclear leukocytes. J. Rheumatol. 13 (1986) 47-51
40. Pistritto G., Franzese O., Pozzoli G., Mancuso C., Tringali G., Preziosi P., and Navarra P. Bacterial lipopolysaccharide increases prostaglandin production by rat astrocytes via inducible cyclo-oxygenase: evidence for the involvement of nuclear factor kappa B. Biochem. Biophys. Res. Co. 263 (1999) 570-574
41. Ristimäki A., Narko K., and Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem. J 318 (1996) 325-331
42. Sander O., Herborn G., Bock E., and Rau R. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Ann. Rheum. Dis. 58 (1999) 281-287
43. Sawaoka H., Dixon D.A., Oates J.A., and Boutaud O. Tristetraprolin binds to the 3′-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J. Biol. Chem. 278 (2003) 13928-13935
44. Seitz M., Dewald B., Ceska M., Gerber N., and Baggiolini M. Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol. Int. 12 (1992) 159-164
45. Seitz M., Valbracht J., Quach J., and Lotz M. Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J. Clin. Immunol. 23 (2003) 477-484
46. Sengupta S., Jang B.C., Wu M.T., Paik J.H., Furneaux H., and Hla T. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J. Biol. Chem. 278 (2003) 25227-25233
47. Sfikakis P.P., Souliotis V.L., and Panayiotidis P.P. Suppression of interleukin-2 and interleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclear cells. Arthritis Rheum. 36 (1993) 208-212
48. Sheng H., Shao J., Dixon D.A., Williams C.S., Prescott S.M., Dubois R.N., and Beauchamp R.D. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275 (2000) 6628-6635
49. Siegle I., Klein T., Backman J.T., Saal J.G., Nusing R.M., and Fritz P. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human synovial tissue: differential elevation of cyclooxygenase-2 in inflammatory joint diseases. Arthritis Rheum. 41 (1998) 122-129
50. Stern I., Wataha J.C., Lewis J.B., Messer R.L., Lockwood P.E., and Tseng W.Y. Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. Toxicol. In Vitro 19 (2005) 365-371
51. Subbaramaiah K., Marmo T.P., Dixon D.A., and Dannenberg A.J. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem. 278 (2003) 37637-37647
52. Tchen C.R., Brook M., Saklatvala J., and Clark A.R. The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself. J. Biol. Chem. 279 (2004) 32393-32400
53. Thiel A., Heinonen M., Rintahaka J., Hallikainen T., Hemmes A., Dixon D.A., Haglund C., and Ristimäki A. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J. Biol. Chem. 281 (2006) 4564-4569
54. Turini M.E., and Dubois R.N. Cyclooxygenase-2: a therapeutic target. Ann. Rev. Med. 53 (2002) 35-57
55. van Beuningen H.M., Stoop R., Buma P., Takahashi N., van der Kraan P.M., and van den Berg W.B. Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage. Osteoarthr. Cartilage 10 (2002) 977-986
56. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Ann. Rev. Pharm. Tox. 38 (1998) 97-120
57. Vargas S.J., Jones T.G., Hurley M.M., and Raisz L.G. Comparison of the effects of auranofin, gold sodium thiomalate, and penicillamine on resorption of cultured fetal rat long bones. J. Bone Miner. Res. 2 (1987) 183-189
58. Vuolteenaho K., Kujala P., Moilanen T., and Moilanen E. Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage. Scand. J. Rheumatol. 34 (2005) 475-479
59. Walz D.T., DiMartino M.J., Griswold D.E., Intoccia A.P., and Flanagan T.L. Biologic actions and pharmacokinetic studies of auranofin. Am. J. Med. Sci. 75 (1983) 90-108
60. 2 production. Current Drug Targets - Inflamm. Allergy 2 (2003) 216-223
61. Yanni G., Nabil M., Farahat M.R., Poston R.N., and Panayi G.S. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann. Rheum. Dis. 53 (1994) 315-322
62. Yu W., Murray N.R., Weems C., Chen L., Guo H., Ethridge R., Ceci J.D., Evers B.M., Thompson E.A., and Fields A.P. Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J. Biol. Chem. 278 (2003) 11167-11174